Camargo Pharmaceutical Services (Formulation rights for solifenacin) is Buildings and Property in United States that focus on urinary incontinence business. They cover business area such as a right, formulation, overactive bladder, a drug, uncontrollable and sudden urge, elderly man, woman, urinary incontinence.
-
Urinary Incontinence
-
9825 Kenwood Road
Suite 203
Cincinnati, OH 45242
United States
Private
a rightformulationoveractive bladdera druguncontrollable and sudden urgeelderly manwomanurinary incontinence
* We use standard office opening hours in near Camargo Pharmaceutical Services (Formulation rights for solifenacin)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Camargo Pharmaceutical Services (Formulation Rights For Solifenacin) is Buildings and Property business from United States that founded in - ( years old in ), Camargo Pharmaceutical Services (Formulation rights for solifenacin) business is focusing on Urinary Incontinence.
Camargo Pharmaceutical Services (Formulation rights for solifenacin) headquarter office and corporate office address is located in 9825 Kenwood Road Suite 203 Cincinnati, OH 45242 United States.
Camargo Pharmaceutical Services (Formulation rights for solifenacin) was founded in United States.
In , Camargo Pharmaceutical Services (Formulation rights for solifenacin) is currently focus on urinary incontinence sector.
Above is snippet of Google Trends for "urinary incontinence" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Camargo Pharmaceutical Services (Formulation rights for solifenacin), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
